本課程將解決臨床醫生需要了解與迷幻輔助心理治療相關的歷史、科學、神經生物學以及倫理和法律問題。
網址:
https://pll.harvard.edu/course/psychedelic-assisted-psychotherapy-next-frontier?delta=0

你會學到什麼

• 識別經典和新型迷幻劑
• 定義什麼是迷幻輔助心理治療 (PAP)
• 描述可能支持 PAP 的心理治療模型
• 為公眾、臨床實踐和研究總結迷幻藥的法律地位
• 查看課程註冊頁面以了解其他學習目標

迷幻輔助心理治療：下一個前沿
PSYCHEDELIC-ASSISTED PSYCHOTHERAPY: THE NEXT FRONTIER

非普通的意識狀態，如催眠和自由聯想，從一開始就在心理治療中發揮了重要作用。最近，我們看到關於藥物致幻劑引起的非正常狀態臨床應用的研究呈爆炸式增長。MDMA 和裸蓋菇素正在美國 FDA 批准的試驗以及政府批准的國外研究中進行研究，以加強對 PTSD、抑鬱症和成癮的心理治療，並緩解臨終過渡。氯胺酮越來越多地用於臨床治療抑鬱症。心理治療與迷幻治療相結合是一種新的心理治療和精神藥理學治療模式，為相互增強神經可塑性、轉變和拓寬視野提供了有趣的可能性，
Non-ordinary states of consciousness, such as hypnosis and free association, have played an important role in psychotherapy since its inception. More recently, we are seeing an explosion of research on the clinical application of non-ordinary states induced by pharmaceutical psychedelics. MDMA and psilocybin are being studied in FDA-approved trials in the United States, as well as government-sanctioned studies abroad, to enhance psychotherapy for PTSD, depression, and addictions, and to ease end-of-life transitions. Ketamine is increasingly used in clinical settings for the treatment of depression. Psychotherapy in combination with psychedelic treatment is a new treatment model for both psychotherapy and psychopharmacology, offering intriguing possibilities for mutually enhancing neuroplasticity, shifting and broadening perspective, and expanding awareness rather than suppressing symptoms.

臨床醫生也越來越需要幫助患者將他們的迷幻體驗融入治療，並為詢問迷幻輔助心理治療的患者提供建議。為了提供知情的建議，臨床醫生需要了解使用迷幻藥的好處和風險，以及提高安全性和減少傷害的治療模式。
There is also a growing need for clinicians to help patients integrate their psychedelic experiences in therapy and to advise patients who ask about psychedelic-assisted psychotherapy. To provide informed counsel, clinicians need to know about the benefits and risks of using psychedelics as well as treatment models that enhance safety and reduce harm.

假設對照研究的結果繼續證實其療效，在治療師可以向患者提供迷幻輔助心理治療之前，還需要更多的研究和培訓。還需要進行額外的工作以使這些治療適應來自不同文化的患者，特別是歷史上被邊緣化的人群。
More research and training will be needed before psychedelic-assisted psychotherapy can be offered by therapists to their patients, assuming the results of controlled studies continue to confirm its efficacy. Additional work is also required to adapt these treatments to patients from diverse cultures, especially historically marginalized populations.

本課程將解決臨床醫生需要了解與迷幻輔助心理治療相關的歷史、科學、神經生物學以及倫理和法律問題。它將為臨床醫生提供他們評估自己對這一新興研究和實踐領域的興趣和參與情況所需的信息。
This course will address clinicians’ need to understand the history, science, neurobiology, and ethical and legal issues associated with psychedelic-assisted psychotherapy. It will provide clinicians the information they require to evaluate their own interest and participation in this emerging field of research and practice.

學習目標

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

目標聽眾

本課程面向初級保健醫師、專科醫師、心理學家、醫師助理、護士、執業護士、社會工作者和顧問。從事家庭醫學、內科、生活方式和身心醫學、精神病學和神經病學、心理學和心理健康領域的醫生也可能對本課程感興趣。

課程主任

Karen J. Kuc，公共衛生碩士
Christopher K. Germer，博士
Ronald D. Siegel，心理學博士
Laura Warren，醫學博士